Determining Activity of ADC + IO Combinations Through Preclinical Tumor Models
Time: 11:00 am
day: Day One AM - Track 2
Details:
- Considerations when developing immunocompetent models to study ADC activity
- Syngeneic v humanized models – rationale and challenges
- Optimizing clinical relevance – dose and schedule selection
